MS treatment study investigates disparities in access and outcomes
NCT ID NCT05131984
First seen Nov 25, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic background influenced how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12-24 months. The goal is to identify any unfair differences in treatment access or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.